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ABSTRACT
Recently, several genetic variants have been associated 
with increased or decreased risks of becoming infected 
and/or seriously ill with COVID-19—not only offering 
important potential medical benefits but also posing 
critical ethical questions. These genetic factors, some of 
which are associated with blood type, may account for 
variations in observed responses to COVID-19. Hence, 
assessments of these genetic differences and blood type 
could provide possible benefits in gauging patients’ 
risks of disease acquisition and prioritising allocation 
of interventions or vaccines, if supplies are limited. The 
media has widely reported these findings, and people 
online are now discussing their blood type and its 
possible effects on their COVID-19 risks, but several 
ethical concerns arise. Individuals possessing genetic 
variants or blood types associated with lower risk may 
engage in ’risk compensation’, erroneously assuming 
that they can protect themselves less, and hence less 
frequently wearing masks or washing hands. Given 
the ongoing COVID-19 pandemic, many physicians, 
hospitals, patients, policymakers, members of the public, 
testing companies and others may well consider these 
factors in making critical prevention/treatment decisions. 
Researchers, providers and others should thus begin 
to address these concerns. Increased awareness and 
education aimed at providers, patients, family members, 
public health officials, political leaders and the public- at- 
large are critical. Attitudinal research is vital to examine 
how providers, patients and the public understand these 
findings. Ethical frameworks and guidelines are needed, 
addressing whether such genetic information should be 
incorporated into decisions regarding allocation of scarce 
resources—including hospital and ICU beds, ventilators, 
medications (eg, remdesivir) and vaccines—and if so, 
how.
Recently, several genetic variants have been asso-
ciated with increased or decreased risks becoming 
infected with COVID-19 or seriously ill, if 
infected1—not only offering important potential 
medical benefits but also posing several critical 
questions. Investigators see potential ‘usefulness’ 
of testing for these genetic factors in ‘clinical risk 
profiling of patients’.1 Especially since limited 
resources for COVID-19 prevention and treatment 
will likely continue, additional types of testing and 
assessment can potentially help in making difficult 
prevention and treatment decisions.
GENETIC DIFFERENCES ASSOCIATED WITH 
PHYSIOLOGICAL RESPONSES TO COVID-19
Ellinghaus et al1 found associations between severe 
COVID-19 disease, defined as respiratory failure, 
and several genetic markers, including those associ-
ated with blood type. A group of six genes on chro-
mosome 3 heightened risks of respiratory failure 
by 56%1 and are found in about 5% of Euro-
peans, 30% of South Asians and 63% of Bangla-
deshis.2 Genes on chromosome 9 associated with 
blood type O decrease risks of infection by around 
20%–35%, and those associated with type B and 
Rh factor positivity increases the risks by around 
10%–28%.3–6 Rare genetic variants have also been 
associated with immunological defects in response 
to COVID-19.7 In the near future, researchers may 
very well identify additional such genetic markers 
as well.
While these studies have shown relationships 
between blood types and risks of becoming infected 
with COVID-19, the relationships between blood 
type and risk of intubation and death are less clear. 
Though Latz found that blood type was associated 
with infection, but not with intubation or death,6 
Ellinghaus et al1 found that blood type was asso-
ciated with respiratory failure, and blood type has 
been associated with death8 and hospitalisation.9 
Rates of intubation, however, may vary based on 
the practice of individual hospitals and coun-
tries, development of improved interventions and 
advances in treatment over time.
Genetic and serological testing and information 
could thus potentially provide possible benefits, 
helping to gauge patients’ risks of disease acquisi-
tion or needs for more aggressive initial treatment. 
These genetic factors could also affect individuals’ 
differential responses to vaccines and medica-
tions—for example, why a vaccine or treatment is 
effective in only, for instance, 50% of individuals, 
and/or why a vaccine leads to development of anti-
bodies or long- term or short- term immunity in only 
certain subsets of individuals. Such findings could 
thus prompt suggestions that individuals whose 
genetics indicate that they will respond favourably 
should receive priority in receiving these interven-
tions, if supplies are limited.
Yet ethical concerns emerge, posing challenges 
for physicians, researchers, patients and the public. 
The media has widely reported these research 
findings and, anecdotally, many people online and 
elsewhere are now discussing their blood type and 
wondering whether it might affect their odds of 
becoming infected or seriously ill, with some indi-
viduals feeling relieved they have blood type O. As 
Latz said, ‘I’ve had a lot of physicians who are using 
our paper to tell patients not to be overly worried’ if 
they lack type O.10 Though Latz has thus expressed 
concern about overzealous interpretation of some 
of these research findings,10 these concerns and 
these implications have not heretofore examined.
 on A








thics: first published as 10.1136/m






150 Klitzman R. J Med Ethics 2021;47:149–151. doi:10.1136/medethics-2020-106920
Current controversy
23andMe has been asking consumers to participate in research 
to identify genetic variants associated with COVID-19 infection 
and outcomes11 and has reported data indicating that blood type 
and genetic variation are associated with infection and hospi-
talisation.9 The company advertises that a benefit of partici-
pating in this research will be to ‘have the option to learn more 
about yourself through genetics’.11 Whether the company will 
provide results now or in the future to consumers who enter 
the study or seek genetic testing through the company more 
broadly is not yet clear. Given the newness of both COVID-19 
and these genetic discoveries, and the fact that scientific under-
standings about them are still evolving, companies that do not 
yet offer such testing will very likely consider doing so in the 
near future. Given that such companies are already engaging in 
research, they could potentially provide such tests and results to 
consumers as part of research studies that would not necessarily 
require US Federal Food and Drug Administration approval. 
Commercial labs could easily begin genetic testing related to 
COVID-19 responses. Direct- to- consumer and other genetic 
testing companies already offer a wide range of genetic tests, 
even in the absence of clinical utility or any FDA- approved uses 
(eg, purporting to predict risks of opiate addiction).12
Over the upcoming months, desperate to combat the ever- 
rising COVID-19 pandemic, many physicians, patients, policy-
makers, members of the public, testing companies and others 
may thus well consider genetics and blood types in making crit-
ical COVID-19 prevention and treatment decisions.
ETHICAL AND OTHER CONCERNS
Yet use of genetic and blood type information in discussions 
about COVID-19 poses several critical ethical concerns. Indi-
viduals possessing genetics or blood types associated with lower 
risk may erroneously assume that they can protect themselves 
less, and hence less frequently wear masks or wash their hands 
after possible exposures. Conversely, individuals who learn they 
possess risk- increasing genetics or blood types might conse-
quently safeguard themselves more carefully and also face 
added stresses and anxiety. Researchers have described ‘risk 
compensation’, in which people engage in riskier behaviours if 
they have acted in ways that they feel are protective.13 Seat belt 
use, for example, has failed to reduce fatal car accidents, since 
drivers wearing seat belts then compensate and drive faster or 
less cautiously.14 Sunscreen use has raised rates of melanoma, 
since people who apply sunscreen feel that they are now safe to 
expose themselves to more sun.15 Gay and bisexual men who 
take pre- exposure prophylaxis to prevent HIV subsequently use 
condoms less, feeling they are ‘safe’, but increasing their rates of 
chlamydia by 59%, and of any sexually transmitted infections 
by 46%.16
Family members, employers or others could also potentially 
use these factors to encourage or pressure certain individuals 
who have ‘protective genes’ or blood types to return to work 
sooner and/or put themselves at heightened risk. Risk compen-
sation could affect bystanders, too, since lower risk individuals 
who engage in risk compensation and thus forgo masks can still 
be infectious, leading to asymptomatic spread. On the other 
hand, if subsequent genetic research found that lower risk indi-
viduals were actually not infectious, society could potentially 
rely on them more for inperson jobs and to protect more vulner-
able individuals
Crucial social justice concerns surface, too, since distribution 
of these genes and blood types also differ significantly by race 
and ethnicity. In the USA, blood type A, for instance, is found 
among 38% of Caucasians, but only 25.2% of African Ameri-
cans.17 Efforts to incorporate such genes in allocation decisions 
thus need to ensure that these factors are not used in ways that 
exacerbate existing social inequities.
Moreover, many key aspects of the roles of these genetic 
factors remain unknown. Additional variables (eg, age, 
premorbid conditions, gender, race, ethnicity and social determi-
nants of health/exposure, including healthcare access and work-
place and living arrangements) may also affect risks of infection 
and symptoms. These genetic and serological studies may thus 
have several potential limitations, since they vary in how much 
they include these other variables as well as treatment adminis-
tered and other details of patients’ clinical courses. Nonetheless, 
consensus appears to be emerging that COVID-19 infection is 
independently associated with certain blood groups. Investiga-
tions are needed, however, to further elaborate on certain other 
associations reported thus far.
MOVING FORWARD: ADDRESSING CHANGE
The critical ethical concerns presented here need to be addressed 
in several ways. Further research among diverse global popu-
lations is essential to investigate precisely how protective these 
genetic and serological differences may be, especially among 
patients of different ages, ethnicities and prior diagnoses, and 
how physicians, patients and families may interpret or misinter-
pret these factors or integrate them into treatment or preven-
tion decisions. The paucity of data on the prevalence of several 
of these genetic markers in other populations, in particular, is 
striking and needs to be rectified. Attitudinal and behavioural 
research is also vital, to examine systematically how providers, 
patients and the public understand and interpret these find-
ings—whether they feel that genetic or blood type information 
is, or may be, helpful, and if so, how and when, or whether such 
information may affect their COVID-19 prevention or treatment 
decisions, and if so, how, and what factors (eg, socioeconomic 
status, age, race/ethnicity, education, prior disease experience, 
and knowledge of COVID-19, and of patients who have recov-
ered or died) may affect these perceptions.
Educational efforts addressing these challenges are critical, 
earlier rather than later, aimed at providers, patients, family 
members, public health officials, political leaders and the public- 
at- large, including appropriate public health messaging.
Professional associations, bioethicists and others should 
consider developing ethical frameworks and guidelines regarding 
use of these genetic and serologic factors—whether the presence 
or absence of such genes or blood type should be incorporated 
into decisions, and if so, how, and what possible advantages and 
disadvantages may exist—for example, regarding triage and 
allocation of scarce resources, including giving lower or higher 
priority to certain patients in deciding admissions to hospitals 
and/or ICUs, use of ventilators, medications (eg, remdesivir) or 
vaccines, if only limited supplies of these interventions are avail-
able—as has often, and will likely continue to be, the case.
Frameworks for allocation of scarce resources in treating 
COVID-19 have been proposed, mostly taking into account 
Sequential Organ Failure Assessments and emphasising processes 
of transparency and inclusions,18 19 age and comorbidities. 
However, these proposals have not yet incorporated genetic 
or blood type information, which differ in several ways from 
the other factors heretofore considered. Published reports to 
date have tended to examine relationships between COVID-19 
patients clinical outcomes among and other, more apparent and 
routinely obtained comorbidity and sociodemographic, rather 
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than blood type and genotypic information. Genotypic infor-
mation also indicates that certain individuals are at decreased, 
not just increased risk of COVID-19 acquisition and symptom 
severity. While comorbidities divide the population into two 
broad categories of increased risk or not, genotypes segregate 
the population as a whole into three groups—those at decreased, 
increased or unaltered risk.
Knowledge of genetics and types could potentially be used in 
allocation of scarce resources in several ways. For instance, indi-
viduals who, based on their genetics or blood type, would gain 
the most from an intervention may go from very low to very high 
prioritisation. Individuals who are most likely to have a good 
clinical outcome, even if they are not very badly off without the 
intervention, may also increase to higher prioritisation, though 
not as much. Those who would be worst off in the absence of the 
intervention, but less likely to benefit, based on their genetics, 
may increase, but still have relatively low prioritisation.
Frameworks or guidelines concerning genetic and serolog-
ical information should seek to promote both procedural and 
distributive justice, aiming for fair processes, with inclusion of 
all relevant stakeholders, including experts in public health, 
genetics, and COVID-19 prevention and treatment, ethicists 
and representatives of ethnic and racial groups and disability 
communities that are at heightened risk of COVID-19 infection 
and symptoms.
CONCLUSIONS
The identification of genetic variations and blood types associ-
ated with physiological responses to COVID-19 can potentially 
provide important medical and public health benefits,espe-
cially given widespread desperation about the growing global 
pandemic, but also raises critical ethical questions and chal-
lenges that need to be addressed through appropriate education, 
research guidelines and practice. Given the ever- rising global 
pandemic, with its uncertainties due to the newness of the virus, 
and the widespread desire to respond as much as possible, we 
urgently need to consider and prepare to address these issues.
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